Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | OGT | O15294 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 13/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7503486 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL3043379 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL30146353 | 0.76 | PSMB8 (0.61) | MCL1OGTGRM5EPHX2NOS1 | |
| SCHEMBL1285749 | 0.76 | EPHX2 (0.50) | MCL1OGTGRM5EPHX2NOS1 | |
| SCHEMBL5540274 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2NOS1 | |
| SCHEMBL5077255 | 0.76 | PSMB8 (0.61) | MCL1OGTGRM5EPHX2NOS1 | |
| SCHEMBL1137634 | 0.76 | PSMB8 (0.61) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL31686101 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL2484702 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL3849115 | 0.74 | MCL1 (0.47) | MCL1OGTGRM5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | claimed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | MCL1 3966/4885OGT 4294/4885GRM5 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.